Stock Track | Syndax Pharmaceuticals Plunges 9% After-Hours on Q3 Revenue Miss

Stock Track11-04

Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) tumbled 9.08% in after-hours trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's revenue fell short of analyst expectations, overshadowing a slight earnings beat.

Syndax reported Q3 revenue of $45.871 million, missing the consensus estimate of $48 million. This represents a 21% increase from the previous quarter but failed to meet market expectations. The company's earnings per share (EPS) came in at -$0.70, slightly better than the -$0.72 anticipated by analysts.

Despite the EPS beat, investors appear to be focusing on the revenue miss and overall financial performance. The company reported operating expenses of $103.297 million for the quarter and a net loss of $60.715 million. Syndax's cash position remains strong at $456.1 million, which could provide some comfort to long-term investors. However, the market's immediate reaction suggests concerns about the company's growth trajectory and ability to meet revenue expectations in the competitive biopharmaceutical landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128394957?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128394957","market":"hk","top_or_hot":-1,"title":"Stock Track | Syndax Pharmaceuticals Plunges 9% After-Hours on Q3 Revenue Miss","media":"Stock Track","content":"<p>Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) tumbled 9.08% in after-hours trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's revenue fell short of analyst expectations, overshadowing a slight earnings beat.</p>\n\n<p>Syndax reported Q3 revenue of $45.871 million, missing the consensus estimate of $48 million. This represents a 21% increase from the previous quarter but failed to meet market expectations. The company's earnings per share (EPS) came in at -$0.70, slightly better than the -$0.72 anticipated by analysts.</p>\n\n<p>Despite the EPS beat, investors appear to be focusing on the revenue miss and overall financial performance. The company reported operating expenses of $103.297 million for the quarter and a net loss of $60.715 million. Syndax's cash position remains strong at $456.1 million, which could provide some comfort to long-term investors. However, the market's immediate reaction suggests concerns about the company's growth trajectory and ability to meet revenue expectations in the competitive biopharmaceutical landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Syndax Pharmaceuticals Plunges 9% After-Hours on Q3 Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Syndax Pharmaceuticals Plunges 9% After-Hours on Q3 Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) tumbled 9.08% in after-hours trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's revenue fell short of analyst expectations, overshadowing a slight earnings beat.</p>\n\n<p>Syndax reported Q3 revenue of $45.871 million, missing the consensus estimate of $48 million. This represents a 21% increase from the previous quarter but failed to meet market expectations. The company's earnings per share (EPS) came in at -$0.70, slightly better than the -$0.72 anticipated by analysts.</p>\n\n<p>Despite the EPS beat, investors appear to be focusing on the revenue miss and overall financial performance. The company reported operating expenses of $103.297 million for the quarter and a net loss of $60.715 million. Syndax's cash position remains strong at $456.1 million, which could provide some comfort to long-term investors. However, the market's immediate reaction suggests concerns about the company's growth trajectory and ability to meet revenue expectations in the competitive biopharmaceutical landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"","article_id":"1128394957","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128394957","pubTimestamp":1762205567,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) tumbled 9.08% in after-hours trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"个股追踪|Syndax Pharmaceuticals盘后暴跌9%因第三季度营收未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) tumbled 9.08% in after-hours trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's revenue fell short of analyst expectations, overshadowing a slight earnings beat.\nSyndax reported Q3 revenue of $45.871 million, missing the consensus estimate of $48 million. This represents a 21% increase from the previous quarter but failed to meet market expectations. The company's earnings per share (EPS) came in at -$0.70, slightly better than the -$0.72 anticipated by analysts.\nDespite the EPS beat, investors appear to be focusing on the revenue miss and overall financial performance. The company reported operating expenses of $103.297 million for the quarter and a net loss of $60.715 million. Syndax's cash position remains strong at $456.1 million, which could provide some comfort to long-term investors. However, the market's immediate reaction suggests concerns about the company's growth trajectory and ability to meet revenue expectations in the competitive biopharmaceutical landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128394957","isCrawlerRequest":true}